An update on LDL apheresis for nephrotic syndrome.
Creator
Raina Rupesh; Krishnappa Vinod
Publisher
Pediatric nephrology (Berlin, Germany)
Date
2018
2018-09
Description
Low-density lipoprotein (LDL) apheresis has been used increasingly in clinical practice for the treatment of renal diseases with nephrotic syndrome (NS), specifically focal segmental glomerulosclerosis (FSGS). Persistent hyperlipidemia for prolonged periods is nephrotoxic and leads to chronic progressive glomerular and tubulointerstitial injury. Effective management of hyperlipidemia with
Extracorporeal Therapies in the Treatment of Focal Segmental Glomerulosclerosis.
Creator
Raina Rupesh; Wang Joseph; Sharma Aditya; Chakraborty Ronith
Publisher
Blood purification
Date
2020
2020-02
Description
Focal segmental glomerulosclerosis (FSGS) is one of the most frequent and severe glomerular kidney disease with frequent progression to end-stage renal disease and a high rate of recurrence in renal transplantations. Due to intolerance or resistance to the current immunomodulatory treatments, the management of FSGS is a therapeutic challenge. Over the last few years, development in extracorporeal therapies has shown potential beneficial outcomes in drug-resistant and recurrent FSGS patients. Thus, this study reviews the current literature on the use of extracorporeal therapies, such as plasma exchange therapy, immunoadsorption, and low-density lipoprotein apheresis, for the treatment of FSGS in the pediatric population.